linjc16/ctgov huggingface dataset:
Sensory Assessment and Regression Rate of Bilateral External Oblique Intercostal Block and m-TAPA Block

Study Overview
=================
Brief Summary
-----------------
External oblique and m-tapa blocks are routinely performed on patients undergoing laparoscopic cholecystectomy in our clinic. In this study, sensory block and regression rates will be investigated in patients who underwent block.

Detailed Description
-----------------
External oblique block and m-Tapa blocks may be the key to provide adequate analgesia in patients undergoing abdominal surgery by blocking the abdominal nerves. In this study, the sensory dermatome block area calculation and the regression rate of the blocks will be evaluated in patients who underwent EOIB and m-Tapa.

Official Title
-----------------
Sensory Assessment and Regression Rate of Bilateral External Oblique Intercostal Block and m-TAPA Block in Patients Undergoing Laparoscopic Cholecystectomy

Conditions
-----------------
Pain, Postoperative, Pain, Acute, Pain

Intervention / Treatment
-----------------
* Procedure: External Oblique Block
* Procedure: m-TAPA block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing L/S cholecystectomy Exclusion Criteria: patients who do not want to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| External Oblique Intercostal Block Group<br>Sensory Assessment and Regression Rate will be performed on the anterolateral abdominal wall after EOIB. (external oblique intercostal block) | Procedure: External Oblique Block<br>* Patients will be followed after EOIB which are routinely performed in our clinic.<br>|
| modified-TAPA block<br>Sensory Assessment and Regression Rate will be performed on the anterolateral abdominal wall after m-Tapa. (modified- thoracoabdominal nerves block through perichondrial approach) | Procedure: m-TAPA block<br>* m-TAPA block<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensory Assessment on the anterolateral abdominal wall | Sensory Assessment will be performed on patients following the block procedure with pinprick test. | 24 hours | 
| Regression Rate of the cutaneous block on anterolateral abdominal wall | Regression Rate will be performed on patients following the block procedure with pinprick test. | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain scores (NRS) in 24 hours following surgery | NRS scores will be followed after surgery | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cutaneous block, Sensory Assessment, Regression Rate
Safety and Feasibility of the ELIOS System in POAG Patients

Study Overview
=================
Brief Summary
-----------------
Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG)

Official Title
-----------------
A Prospective, Multicenter, Clinical Trial Designed to Evaluate the Safety and Feasibility of the ELIOS System to Reduce Intraocular Pressure in Patients With Primary Open-Angle Glaucoma as a Standalone Procedure

Conditions
-----------------
Glaucoma, Primary Open Angle

Intervention / Treatment
-----------------
* Device: ELIOS Procedure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of mild to moderate POAG Medicated IOP of <=24 mmHg Shaffer angle grade of III or IV CD ratio <=0.8 At least 45 years old Exclusion Criteria: Closed-angle and secondary glaucomas Prior incisional glaucoma surgery, intraocular surgery, or corneal surgery Cannot undergo medication washout in the study eye Diagnosis of degenerative visual disorders Non-study eye with BCVA worse than 20/80 Known corticosteroid responder Pregnant or nursing women; or women of childbearing potential not using medically acceptable birth control

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ELIOS Procedure<br>ELIOS Procedure | Device: ELIOS Procedure<br>* Treatment with the ELIOS System<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of subjects who achieve a decrease in mean diurnal IOP (DIOP) from baseline of at least 20% on the same or fewer medications | Proportion of subjects who achieve a decrease in mean diurnal IOP (DIOP) from baseline of at least 20% on the same or fewer medications | 12 Months | 
| Mean Change in DIOP from baseline on the same or fewer medications | Mean Change in DIOP from baseline on the same or fewer medications | 12 Months |
Study on the Effect of Target-controlled Infusion for General Anesthesia in Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of the study was to evaluate whether individualized general anesthesia with target-controlled infusion could help patients wake up early for extubation and reduce the incidence of postoperative complications, and to investigate the effectiveness and safety of its application in patients undergoing cardiac surgery.

Official Title
-----------------
Study on the Effect of Target-controlled Infusion of Propofol and Remifentanil for Patients Undergoing Cardiac Surgery

Conditions
-----------------
Postoperative Mechanical Ventilation Time

Intervention / Treatment
-----------------
* Device: Target-controlled infusion (TCI) systems


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients aged 18 years and older who underwent cardiac surgery Exclusion Criteria: Mechanical ventilation support before surgery; Combined with any type of non-cardiac surgeries; Second exploratory thoracotomy after surgery; Died or discharged within 48 h after surgery; Missing clinical data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TCI group<br>patients receiving general anesthesia using target-controlled infusion delivery system | Device: Target-controlled infusion (TCI) systems<br>* Target-controlled infusion (TCI) with propofol and remifentanil was used for anesthesia induction and maintenance<br>|
| MCI group<br>patients receiving general anesthesia using conventional manual controlled infusion delivery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of postoperative mechanical ventilation | Duration of mechanical ventilation was defined as the time from the end of surgery to tracheal extubation | 4 weeks after surgery |
Changes of Low Anterior Resection Syndrome and Balance Ability in Patients With Rectal Cancer.

Study Overview
=================
Brief Summary
-----------------
The purposes of this study are to explore the trajectory of symptom distress and balance ability in patients with rectal cancer.

Official Title
-----------------
Changes of Low Anterior Resection Syndrome, Balance Ability, and Quality of Life in Patients With Newly Diagnosed Rectal Cancer.

Conditions
-----------------
Rectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed rectal cancer Patients already know their condition. Aged 20 years and older. Consciously communicate in Mandarin or Taiwanese. Agreed with the interview and had signed the permit. Exclusion Criteria: Recurrent rectal cancer. KPS of patients less than 80

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Low Anterior Resection Syndrome | Total score 0-42 | Change from baseline symptom at 2 months |
Evaluation of Physiological Variables and Detection of Blood Loss in Healthy Adults With Different Subject Positioning by the CM-1500

Study Overview
=================
Brief Summary
-----------------
The study is a prospective, non-randomized, non-blinded, non-significant risk study enrolling up to 60 healthy adult subjects consented to undergo a 1-unit whole blood draw procedure. Subjects will wear the study device (CM-1500) while positioned in either a supine or reclined position during the blood draw and study-required physiological parameters will be captured pre-, during, and post-donation.

Official Title
-----------------
Evaluation of Physiological Variables and Detection of Blood Loss in Healthy Adults With Different Subject Positioning by the Zynex Cardiac Monitor, Model 1500 (CM-1500)

Conditions
-----------------
Fluid Loss, Blood Loss

Intervention / Treatment
-----------------
* Device: Whole blood donation supine
* Device: Whole blood donation reclined


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to provide written informed consent Ability and willingness to comply with the study procedures and duration requirements 18 years of age or older Consented and eligible to undergo a single unit whole blood donation Exclusion Criteria: Females who are pregnant or breastfeeding Undergone an amputation of any upper extremity Diagnosed with dextrocardia Subjects who have a pacemaker Subjects with body hair density which prevents adequate application of device electrodes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Supine Donation Position<br> | Device: Whole blood donation supine<br>* Subjects will undergo a 1-unit whole blood donation in a supine position<br>|
| Experimental: Reclined Donation Position<br> | Device: Whole blood donation reclined<br>* Subjects will undergo a 1-unit whole blood donation in a reclined position<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of subject positioning on percent change of physiological parameters during minor blood loss | Percent change in heart rate, forearm skin temperature, bioelectrical impedance, ECG amplitude and PPG amplitude before and after blood draw in either a reclined or supine position. | At completion of blood draw |
Lock sOlutiOnS for Epicutaneo-caval Catheters in Neonates: a LOOSEN Pilot Study

Study Overview
=================
Brief Summary
-----------------
Epicutaneo-caval catheters (ECCs) are widely used in neonatal intensive care units (NICUs). They are small catheters inserted via superficial veins of the limbs or scalp using direct vein visualization The pathogenic microorganisms colonized inside catheters can easily form a bacterial biofilm and eventually spread with blood flow which causes bloodstream infection. Many authors have studied the antibiotic-lock therapy (ALT) in which a high-dose antibiotic solution is dripped and maintained in the catheter cavity for a certain period and can dissolve the biofilm formed on the wall to reduce the colonization of the bacteria and kill the embedded bacteria.The aim of the study is to evaluate the patency of the Epicutaneo-caval catheter after its closure for 1 hour.

Official Title
-----------------
Lock sOlutiOnS for Epicutaneo-caval Catheters in Neonates: a LOOSEN Pilot Study

Conditions
-----------------
Catheter-related Bloodstream Infection, Preterm, Catheter Infection, Catheter Complications

Intervention / Treatment
-----------------
* Combination Product: neutrox


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the Epicutaneo-caval catheter that need to be removed electively will be included in the study - Exclusion Criteria: All the Epicutaneo-caval catheters removed not electively but for infectious or mechanical complications will be excluded from the study. -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Epicutaneo-caval catheter removed electively<br>This is a pilot study designed to evaluate the patency of the Epicutaneo-caval catheter after its closure for 1 hour in order to assess the feasibility of possible Taurolidine lock-terapy in Epicutaneo-Caval Catheters. | Combination Product: neutrox<br>* Each ECC, after discontinuing the Parental Nutrition (NP) infusion, will be flushed with 0.3 ml saline. Subsequently, Saline will be infused at a rate of 2 ml/h for 10 minutes. The ECC will then be closed for 1 hour. At the end of the hour the ECC will be once again flushed with 0.3 ml Saline and infused with SF at the rate of 2 cc/h for 10 minutes. The difference in pressure of the two infusions, before and after catheter closure, will be evaluated.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pressure level mmHg | The aim of the study is to evaluate the patency of the Epicutaneo-caval catheter after its closure for 1 hour. | 1 hours |
The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT

Study Overview
=================
Brief Summary
-----------------
To identify the incidence of LIT among critically ill patients, as limited studies have only addressed this population. To evaluate the impact of several factors on the incidence of LIT, the time to onset of LIT, and the time to recovery of platelets. To study the effect of concurrent medications (enoxaparin, unfractinated heparin, piperacillin, carbapenems, tigecycline, fluconazole or voriconazole, digoxin, amiodarone, acetaminophen, tirofiban, statins, and antiepileptics) frequently used in critically ill patients on the incidence of LIT. To investigate the impact of possible medications with an antioxidant effect on the prevention of LIT. To assess the impact of LIT on composite end point (mortality, bleeding, and length of stay)

Official Title
-----------------
The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT and Time to Events (LIT, Recovery)

Conditions
-----------------
Thrombocytopenia; Drugs

Intervention / Treatment
-----------------
* Drug: Linezolid 600 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All adult patients, age > or = 18 years old, admitted to the ICU with different indications. candidates for intravenous linezolid therapy for > or =1 day. Exclusion Criteria: Taking any myelosuppressive drug. Baseline platelets < 50000. Patients with hematological malignancy. COVID-19 patients. Patients with immune thrombocytopenia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Single arm group<br>Adult critically ill patients admitted to ICU for different indications | Drug: Linezolid 600 mg<br>* Linezolid 600mg injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Linezolid-induced thrombocytopenia (LIT) thrombocytopenia | Defined as platelets < 150000 OR decrease > 50% of baseline platelets. | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to the onset of LIT | Defined as platelets < 150000 OR decrease > or = 50% of baseline platelets. | One year | 
| time to platelet recovery | after having thrombocytopenia, regardless of discontinuation of linezolid, recovery is defined as the restoration and maintenance of platelet counts > 70% of baseline values | One year | 
| Incidence of clinical outcomes | Incidence of clinical outcomes (bleeding, mortality, length of stay, need for platelet or blood transfusion). | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Linezolid, Thrombocytopenia
Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer

Study Overview
=================
Brief Summary
-----------------
DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.

Official Title
-----------------
Retrospective and Prospective Evaluation of the Impact of Innovative and Conventional Treatments and of Clinical Variables on the Outcome of Thyroid Cancer

Conditions
-----------------
Thyroid Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - thyroid cancer diagnosis Exclusion Criteria: patients unable to sign informed consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dynamic risk stratification | impact of the different variables on the DRS | one year from the primary treatment | 
| Dynamic risk stratification | impact of the different variables on the DRS | five years from the primary treatment | 
| Dynamic risk stratification | impact of the different variables on the DRS | ten years from the primary treatment | 
| Progression-free survival | impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer | one year from the primary treatment | 
| Progression-free survival | impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer | five years from the primary treatment | 
| Progression-free survival | impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer | ten years from the primary treatment | 
| Overall survival | impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer | one year from the primary treatment | 
| Overall survival | impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer | five years from the primary treatment | 
| Overall survival | impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer | ten years from the primary treatment |
Microbiological Profile of VAP Patients in Respiratory ICU

Study Overview
=================
Brief Summary
-----------------
Identification of the microbial profile of Ventilator associated pneumonia causing microorganisms among Respiratory ICU patients .

Detailed Description
-----------------
Ventilator-associated pneumonia (VAP) is one of the common serious infectious diseases encountered in the intensive care unit (ICU), which highly affects the healthcare cost and patient prognosis. All-cause of mortality associated with VAP has been reported to range from 20% to 50%. The etiology of VAP and their antimicrobial susceptibility pattern varies with different patient populations and types of ICUs. VAP may be caused by a wide spectrum of bacterial pathogens, which may be polymicrobial and are rarely due to viral or fungal pathogens in immune-competent hosts. Common etiologic agents are Gram-negative bacilli such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter spp. and Staphylococcus aureus among Gram-positive cocci. Due to the increased incidence of MDR organisms in Intensive Care Units (ICUs), early and correct diagnosis of VAP is mandatory for optimal antibiotic therapy. The frequency of specific MDR pathogens causing VAP varies in hospitals, patient populations. Also varies according underlying disease. this study will be conducted in respiratory intensive care unit, chest disease and tuberculosis department at Assiut university hospitals.

Official Title
-----------------
Microbiological Profile of Ventilator Associated Pneumonia in Respiratory Intensive Care Unit of Assiut University Hospital

Conditions
-----------------
VAP - Ventilator Associated Pneumonia

Intervention / Treatment
-----------------
* Diagnostic Test: blood and sputum culture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mechanically ventilated patient who developed pneumonia after48 hours after endotracheal intubation. Age > 18 years. Exclusion Criteria: Patients with clinical and radiological signs suggestive of pneumonia before intubation (community acquired pneumonia or hospital acquired pneumonia) Patients age ≤18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: blood and sputum culture|Noninvasive sampling ( Endo Tracheal Aspiration) for staining and culture. Blood culture .|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microbiological profile of ventilator associated pneumonia in Respiratory ICU in Assiut University Hospital. | Identify the microbial profile of VAP causing microorganisms among ICU patients, antimicrobial susceptibility patterns among the frequently isolated organisms and resistant strains. | 1 year |